Reviewed by Michael Gill, B. Sc.
25 Gastric Cancer Clinical Trials Near Me
Top Hospitals for Gastric Cancer Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
7Active Trials
21All Time Trials for Gastric Cancer
2004First Gastric Cancer Trial
Image of The University of Texas MD Anderson Cancer Center in Texas.
The University of Texas MD Anderson Cancer Center
Houston
5Active Trials
8All Time Trials for Gastric Cancer
2009First Gastric Cancer Trial
Top Cities for Gastric Cancer Clinical Trials
Most Recent Gastric Cancer Clinical Trials
Top Treatments for Gastric Cancer Clinical Trials
Treatment Name
Active Gastric Cancer Clinical Trials
All Time Trials for Gastric Cancer
First Recorded Gastric Cancer Trial
Nivolumab
3
21
2015
Chemotherapy
2
16
2008
Pembrolizumab
2
40
2015
Radiation Therapy
2
6
2016
Trastuzumab deruxtecan
2
2
2019
Recently Completed Studies with FDA Approved Treatments for Gastric Cancer
Treatment
Year
Sponsor
Somatuline Depot
2017
Duke University

What Are Gastric Cancer Clinical Trials?

Gastric cancer is one of the leading cancers in the world and is formed in the stomach lining. Stomach disease, diet, and age impact the risk of this cancer. The risk factors also include inherited conditions, H. pylori bacteria, and smoking. The symptoms include stomach pain or discomfort and indigestion.

Why Is Gastric Cancer Being Studied Through Clinical Trials?

Stomach cancer makes up about 1.5% of overall cancers diagnosed annually in the US. There are around 26,380 new gastric cancer and 11,090 fatalities annually. Gastric cancer is a significant health issue in the world. It is the 5th leading and 3rd deadliest cancer in the world, which is why finding effective treatments, preventive measures, and a cure through clinical trials and research is integral.

What Are The Types of Treatments Available For Gastric Cancer?

The treatment for stomach cancer is usually successful if cancer has been contained in the stomach and the prognosis for it is good. However, the diagnosis of gastric cancer is found once it has spread in most cases, making the cure more challenging. The treatment is based on the severity of cancer.

The major treatments for gastric cancer include:

  • Chemotherapy for stomach cancer

  • Immunotherapy for stomach cancer

  • Radiation therapy for stomach cancer

  • Surgery for stomach cancer

    Targeted drug therapy for stomach cancer

What Are Some Recent Breakthrough Clinical Trials For Gastric Cancer?

2022: A clinical trial found the combination of pembrolizumab and chemotherapy as an effective treatment for gastroesophageal junction or gastric cancer. The standard treatment for gastric cancer is chemotherapy, but not all patients get beneficial results, which is why more treatment options are needed. The researchers tested the combination of these drugs among patients who can't handle triple chemotherapy and found optimistic results. The trial is now entering its third phase and is expected to alter the treatment options for gastric cancer.

2021: FDA granted approval to Opdivo (nivolumab) combined with different chemotherapy as an initial treatment for metastatic or advanced gastric cancer, esophageal adenocarcinoma, and gastroesophageal junction cancer. Nivolumab is the first immunotherapy approved by FDA as a first-line treatment for this cancer. This treatment is the first in over a decade with the potential to improve the survival rate of the patients getting first-time treatment.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Gastric Cancer Clinical Trials Research?

GI Cancers Alliance: This association is dedicated to spreading awareness and funding research for gastrointestinal cancers. It helps address the growing need for treatment, awareness, and screening of gastric cancer.

Gastric Cancer Foundation: This institution offers grants and funds to researchers working on projects and clinical trials related to under-funded diseases, particularly gastric cancer, to find a cure and effective preventive measures. The foundation launched a Gastric Cancer Registry to encourage and expand research and provide a practical and centralized resource for individuals with gastric cancer. The center also establishes partnerships and alliances to promote more investments in research and trials related to gastric cancer.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: November 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31. https://pubmed.ncbi.nlm.nih.gov/260284072 Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27. https://pubmed.ncbi.nlm.nih.gov/264124563 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. https://pubmed.ncbi.nlm.nih.gov/260282554 Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18. https://pubmed.ncbi.nlm.nih.gov/260957855 Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24. https://pubmed.ncbi.nlm.nih.gov/277891966 Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19. https://pubmed.ncbi.nlm.nih.gov/267120847 Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. https://pubmed.ncbi.nlm.nih.gov/257543298 Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13. Erratum in: Lancet. 2017 Apr 8;389(10077):e5. https://pubmed.ncbi.nlm.nih.gov/279793839 Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. https://pubmed.ncbi.nlm.nih.gov/2899305210 Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24. https://pubmed.ncbi.nlm.nih.gov/27789196